Waters (WAT) Stock
Global lab instrument maker for drug development and testing. Here's the price, business snapshot, and what's worth knowing about Waters in May 2026.
Waters Corporation (WAT) designs and manufactures laboratory analytical instruments — notably high-performance liquid chromatography and mass spectrometry systems — used to separate, identify and quantify chemical compounds. Its products, consumables and services serve pharmaceutical, biotech, chemical, food-safety and environmental laboratories worldwide. Revenue typically comprises capital equipment sales and recurring aftermarket consumables and service contracts, which can provide resilient cash flow but remain sensitive to capital spending cycles. Waters benefits from a strong installed base, long product lifecycles and regulatory-driven demand in drug development and quality control. Key considerations for investors include exposure to global pharmaceutical investment, competition from other instrument makers, currency and supply-chain risks, and the ongoing need for R&D. Market cap: $20.79B. This is general information for education, not personalised advice; values can rise or fall and past performance is not a guide.
Why It's Moving
Waters is climbing on steady analyst confidence, but the move is being driven more by consensus than fresh catalysts.
- Analyst coverage remains broadly upbeat, with multiple firms maintaining constructive ratings and price targets above the current trading level, reinforcing the idea that expectations for Waters’ fundamentals remain intact.
- The latest target updates suggest investors are still willing to pay for the company’s recurring demand and margin durability, which can help the stock hold up even without a fresh earnings catalyst.
- With no major earnings surprise or corporate announcement in the last seven days, the stock’s tone is being shaped more by analyst positioning and broader healthcare/tools sector sentiment than by a single headline.
Waters is climbing on steady analyst confidence, but the move is being driven more by consensus than fresh catalysts.
- Analyst coverage remains broadly upbeat, with multiple firms maintaining constructive ratings and price targets above the current trading level, reinforcing the idea that expectations for Waters’ fundamentals remain intact.
- The latest target updates suggest investors are still willing to pay for the company’s recurring demand and margin durability, which can help the stock hold up even without a fresh earnings catalyst.
- With no major earnings surprise or corporate announcement in the last seven days, the stock’s tone is being shaped more by analyst positioning and broader healthcare/tools sector sentiment than by a single headline.
When is the next earnings date for WATERS CORP (WAT)?
The next earnings date for Waters Corporation (WAT) is August 3, 2026, based on the current consensus estimate. It is expected to cover Q2 2026 results. This date is still an estimate and has not been officially confirmed by the company.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Waters Corporation's stock with a target price of $372.85, indicating growth potential.
Financial Health
Waters Corporation is performing well with strong revenue, profits, and cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring WAT
Pharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: July 23, 2025
Explore BasketBeyond The Ozarks: Trusted Outdoor Brands
This carefully selected group of stocks represents established outdoor and drinkware brands poised for growth. Our professional analysts have identified these companies as potential beneficiaries of shifting consumer preferences toward trusted, premium products following Walmart's major safety recall.
Published: July 11, 2025
Explore BasketPure Water Plays: Investing in Trusted Alternatives
Following investigations into Nestlé's water filtration practices, consumers may seek more transparent water options. These carefully selected stocks represent companies that could benefit from this shift, from beverage competitors to water purification technology providers.
Published: July 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Aftermarket Revenue Strength
Consumables and service contracts create steady recurring income that can stabilise revenue, though instrument orders remain cyclical and can vary.
Pharma & Regulation Demand
Demand from drug development and regulatory testing supports long-term need for high-end instruments, but exposure to regulatory cycles and geographic shifts adds variability.
Innovation & Competition
Continued R&D keeps the product line competitive in high-precision analytics, yet heavy R&D spend and rival technologies present execution risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
